Drug news
NICE now recommends Gazyvaro for treatment of CLL- Roche
NICE (The National Institute for Health and Care Excellence) has reversed its earlier negative decision on Gazyvaro (obinutuzumab) from Roche for Chronic Lymphocytic Leukemia as Roche has provided further cost effectiveness information. NICE has issued a further guidance recommending Gazyvaro for untreated CLL conditional on a reduction in price.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.